Afagh Garjani
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies
Garjani, Afagh; Middleton, Rodden M; Hunter, Rachael; Tuite-Dalton, Katherine A; Coles, Alasdair; Dobson, Ruth; Duddy, Martin; Hughes, Stella; Pearson, Owen R; Rog, David; Tallantyre, Emma C; das Nair, Roshan; Nicholas, Richard; Evangelou, Nikos
Authors
Rodden M Middleton
Rachael Hunter
Katherine A Tuite-Dalton
Alasdair Coles
Ruth Dobson
Martin Duddy
Stella Hughes
Owen R Pearson
David Rog
Emma C Tallantyre
ROSHAN NAIR Roshan.dasnair@nottingham.ac.uk
Professor of Clinical Psychology and Neuropsychology
Richard Nicholas
NIKOS EVANGELOU Nikos.Evangelou@nottingham.ac.uk
Clinical Professor
Abstract
Background
Infections can trigger exacerbations of multiple sclerosis (MS). The effects of the coronavirus disease 2019 (COVID-19) on MS are not known. The aim of this study was to understand the impact of COVID-19 on new and pre-existing symptoms of MS.
Methods
The COVID-19 and MS study is an ongoing community-based, prospective cohort study conducted as part of the United Kingdom MS Register. People with MS and COVID-19 were invited by email to complete a questionnaire about their MS symptoms during the infection. An MS exacerbation was defined as developing new MS symptoms and/or worsening of pre-existing MS symptoms.
Results
Fifty-seven percent (230/404) of participants had an MS exacerbation during their infection; 82 developed new MS symptoms, 207 experienced worsened pre-existing MS symptoms, and 59 reported both. Disease modifying therapies (DMTs) reduced the likelihood of developing new MS symptoms during the infection (OR 0.556, 95%CI 0.316-0.978). Participants with a higher pre-COVID-19 webEDSS (web-based Expanded Disability Status Scale) score (OR 1.251, 95%CI 1.060-1.478) and longer MS duration (OR 1.042, 95%CI 1.009-1.076) were more likely to experience worsening of their pre-existing MS symptoms during the infection.
Conclusion
COVID-19 infection was associated with exacerbation of MS. DMTs reduced the chance of developing new MS symptoms during the infection.
Journal Article Type | Article |
---|---|
Acceptance Date | Apr 5, 2021 |
Online Publication Date | May 5, 2021 |
Publication Date | 2021-07 |
Deposit Date | May 13, 2021 |
Publicly Available Date | May 6, 2022 |
Journal | Multiple Sclerosis and Related Disorders |
Print ISSN | 2211-0348 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 52 |
Article Number | 102939 |
DOI | https://doi.org/10.1016/j.msard.2021.102939 |
Keywords | Neurology; Clinical Neurology; General Medicine |
Public URL | https://nottingham-repository.worktribe.com/output/5527651 |
Publisher URL | https://www.sciencedirect.com/science/article/pii/S2211034821002066 |
Files
Manuscript_clean_submitted
(193 Kb)
PDF
You might also like
Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis
(2022)
Journal Article
Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis
(2022)
Journal Article
Decentralised clinical trials in multiple sclerosis research
(2022)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search